A Phase 1 trial with pembro combined with MGA271 (Enoblituzumab – an anti-B7-H3 monoclonal antibody) is recruiting for folks with a variety of solid tumors, including melanoma, after having failed at least one immunotherapy and having measurable disease positive for B7-H3. It is phase 1…so it's not a done deal…but everyone gets the meds. Many more people are being helped by ipi and anti-PD1, which is great…but there are those who fail to respond…so if you are in need…this might be something you'd like to talk to your doc about.
And, yes, jpg…before you get your britches in a bunch…this is a link to my blog. It is a post I put together. It contains three links within…more than MPIP spam blockers will allow…as well as photos of slides (not possible for me to upload here)!!
Check it out if you are interested. For what it's worth. I wish you all well. Celeste
Thanks Celeste for the Sunday morning reading!!!! One of these new combinations is going to be a home run, maybe this is the one? I am glad to see that it is being combined with Pd-1 in the hope that it may help with T-cell Immune suppression. Best Wishes!!!Ed
Thanks Celeste for the Sunday morning reading!!!! One of these new combinations is going to be a home run, maybe this is the one? I am glad to see that it is being combined with Pd-1 in the hope that it may help with T-cell Immune suppression. Best Wishes!!!Ed
Thanks Celeste for the Sunday morning reading!!!! One of these new combinations is going to be a home run, maybe this is the one? I am glad to see that it is being combined with Pd-1 in the hope that it may help with T-cell Immune suppression. Best Wishes!!!Ed
The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.
The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.
.
.
